Biomerica (NASDAQ:BMRA – Get Free Report) and Reviva Pharmaceuticals (NASDAQ:RVPH – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends.
Earnings and Valuation
This table compares Biomerica and Reviva Pharmaceuticals”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Biomerica | $4.88 million | 1.45 | -$4.97 million | ($0.96) | -2.51 |
| Reviva Pharmaceuticals | N/A | N/A | -$29.92 million | ($0.46) | -1.09 |
Profitability
This table compares Biomerica and Reviva Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Biomerica | -74.84% | -73.44% | -53.26% |
| Reviva Pharmaceuticals | N/A | -20,501.80% | -187.50% |
Risk and Volatility
Biomerica has a beta of 0.28, meaning that its share price is 72% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Biomerica and Reviva Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Biomerica | 1 | 0 | 0 | 0 | 1.00 |
| Reviva Pharmaceuticals | 1 | 0 | 8 | 0 | 2.78 |
Reviva Pharmaceuticals has a consensus target price of $3.86, indicating a potential upside of 668.05%. Given Reviva Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Biomerica.
Institutional & Insider Ownership
22.3% of Biomerica shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 18.0% of Biomerica shares are owned by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Reviva Pharmaceuticals beats Biomerica on 7 of the 13 factors compared between the two stocks.
About Biomerica
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
About Reviva Pharmaceuticals
Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.
Receive News & Ratings for Biomerica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biomerica and related companies with MarketBeat.com's FREE daily email newsletter.
